无进展生存期：有意义还是仅仅可测量？ - Suppr

Suppr

超能文献

Progression-free survival: meaningful or simply measurable?

作者信息

Booth Christopher M, Eisenhauer Elizabeth A

出版信息

J Clin Oncol. 2012 Apr 1;30(10):1030-3. doi: 10.1200/JCO.2011.38.7571. Epub 2012 Feb 27.

DOI:10.1200/JCO.2011.38.7571

PMID:22370321

Abstract

摘要

相似文献

Progression-free survival: meaningful or simply measurable?无进展生存期：有意义还是仅仅可测量？

J Clin Oncol. 2012 Apr 1;30(10):1030-3. doi: 10.1200/JCO.2011.38.7571. Epub 2012 Feb 27.

Effects of cancer drugs on survival: often poorly evaluated.抗癌药物对生存率的影响：评估往往欠佳。

Prescrire Int. 2009 Aug;18(102):180-3.

Design and endpoints of clinical trials in hepatocellular carcinoma.肝细胞癌临床试验的设计与终点

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.

The ethics of early stopping rules.早期终止规则的伦理问题。

J Clin Oncol. 2005 Apr 20;23(12):2862-3; author reply 2863-4. doi: 10.1200/JCO.2005.05.119.

Cancer Radiother. 2010 Oct;14(6-7):515-8. doi: 10.1016/j.canrad.2010.06.001. Epub 2010 Jul 31.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?2期试验中肿瘤大小的早期平均变化：有效终点还是虚假承诺？

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25.

Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.评估晚期结直肠癌治疗策略的替代终点：无进展生存期、疾病控制持续时间和策略失败时间的评估——一项 Aide et Recherche en Cancerologie Digestive 组研究。

J Clin Oncol. 2011 Nov 1;29(31):4199-204. doi: 10.1200/JCO.2011.35.5867. Epub 2011 Oct 3.

Eleven years: the long and winding road.十一年：漫长而曲折的道路。

Gynecol Oncol. 2007 Nov;107(2):166-8. doi: 10.1016/j.ygyno.2007.09.032.

The ethics of early stopping rules: who is protecting whom?早期终止规则的伦理：谁在保护谁？

J Clin Oncol. 2004 May 1;22(9):1542-5. doi: 10.1200/JCO.2004.02.150.

Letter to the Editor re Yu and Holmgren. Traditional endpoint of progression-free survival (PFS) may not be appropriate for evaluating cytostatic agents combined with chemotherapy in cancer clinical trials.致编辑的信：关于Yu和Holmgren的研究。无进展生存期（PFS）这一传统终点可能不适用于评估癌症临床试验中细胞抑制剂与化疗联合使用的情况。

Contemp Clin Trials. 2007 Sep;28(5):674. doi: 10.1016/j.cct.2007.03.008. Epub 2007 Mar 23.

引用本文的文献

Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan.复发/难治性滤泡性淋巴瘤患者及医生的治疗偏好：美国、英国、法国、德国、巴西和日本的一项离散选择实验

Front Oncol. 2025 Jul 10;15:1589722. doi: 10.3389/fonc.2025.1589722. eCollection 2025.

Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis.现代3期肿瘤学试验中的总生存期和生活质量优势：一项Meta流行病学分析

JAMA Oncol. 2025 Jun 1. doi: 10.1001/jamaoncol.2025.1002.

Computational analysis of whole slide images predicts PD-L1 expression and progression-free survival in immunotherapy-treated non-small cell lung cancer patients.全玻片图像的计算分析可预测接受免疫治疗的非小细胞肺癌患者的PD-L1表达和无进展生存期。

J Transl Med. 2025 May 6;23(1):510. doi: 10.1186/s12967-025-06487-2.

Putting Patients First: Pragmatic Trials in Gynecologic Oncology.将患者放在首位：妇科肿瘤学中的务实试验

Curr Oncol. 2025 Feb 27;32(3):139. doi: 10.3390/curroncol32030139.

Factors in Time to Full Approval or Withdrawal for Anticancer Medicines Granted Accelerated Approval by the FDA.美国食品药品监督管理局（FDA）加速批准的抗癌药物完全获批或撤回所需时间的影响因素。

JAMA Netw Open. 2025 Mar 3;8(3):e252026. doi: 10.1001/jamanetworkopen.2025.2026.

Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.重新定义新辅助化疗治疗高危软组织肉瘤的放射学反应：ISG-STS 1001随机临床试验的最终结果

ESMO Open. 2025 Mar;10(3):104299. doi: 10.1016/j.esmoop.2025.104299. Epub 2025 Mar 7.

Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials.III期肿瘤试验中进展后治疗及对总生存估计治疗效果的混杂因素

BMJ Oncol. 2024 Apr 11;3(1):e000322. doi: 10.1136/bmjonc-2024-000322. eCollection 2024.

A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis.PARP抑制剂作为铂敏感复发性卵巢癌维持治疗的综合比较：一项系统评价和网状Meta分析

J Ovarian Res. 2025 Jan 30;18(1):18. doi: 10.1186/s13048-025-01599-1.

International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set.肛管癌放化疗试验结局定义的国际共识（CORMAC-2）：确定CORMAC核心结局集的结局

EClinicalMedicine. 2024 Dec 5;78:102939. doi: 10.1016/j.eclinm.2024.102939. eCollection 2024 Dec.

Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers.从潜在可治愈的肺癌临床试验中得出的人群生存动力学。

Curr Oncol. 2024 Mar 20;31(3):1600-1617. doi: 10.3390/curroncol31030122.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验